Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA for Depression in Parkinson Disease
NCT03069911Phase 1Terminated
- Sponsor
- Johns Hopkins University
- Start
- Nov 2018
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Botox Arm with Placebo Arm (2 arms). Primary endpoints: Hamilton Rating Scale for Depression at Week 12, Clinical Global Impression - Improvement at Week 12 and 2 more. Started Nov 2018; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03069911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069911.